4//SEC Filing
Hopper Jonathan Mark 4
Accession 0001140361-25-005256
CIK 0000887359other
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 4:05 PM ET
Size
18.3 KB
Accession
0001140361-25-005256
Insider Transaction Report
Form 4
Vericel CorpVCEL
Hopper Jonathan Mark
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-02-18+3,000→ 61,500 total - Exercise/Conversion
Common Stock
2025-02-18+2,325→ 63,825 total - Tax Payment
Common Stock
2025-02-18$57.28/sh−985$56,421→ 62,840 total - Exercise/Conversion
Common Stock
2025-02-19+1,750→ 64,590 total - Tax Payment
Common Stock
2025-02-19$57.78/sh−853$49,286→ 63,737 total - Exercise/Conversion
Restricted Stock Unit
2025-02-18+3,000→ 6,000 total→ Common Stock (3,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-18+2,325→ 2,325 total→ Common Stock (2,325 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-02-19+1,750→ 0 total→ Common Stock (1,750 underlying)
Footnotes (10)
- [F1]The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.
- [F10]The Fair Market Value of the vested derivative securities is $57.78 per share.
- [F2]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2026, and February 17, 2027, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 3,000 shares of Common Stock and instead received 3,000 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.
- [F3]These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F4]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest on February 18, 2026.
- [F5]These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
- [F6]The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021.
- [F7]Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
- [F8]No expiration date for this type of award.
- [F9]The Fair Market Value of the vested derivative securities is $57.28 per share.
Documents
Issuer
Vericel Corp
CIK 0000887359
Entity typeother
Related Parties
1- filerCIK 0001626325
Filing Metadata
- Form type
- 4
- Filed
- Feb 19, 7:00 PM ET
- Accepted
- Feb 20, 4:05 PM ET
- Size
- 18.3 KB